Name | Synta66 |
---|---|
Synonyms |
N-(2',5'-Dimethoxy-4-biphenylyl)-3-fluoroisonicotinamide
4-Pyridinecarboxamide, N-(2',5'-dimethoxy[1,1'-biphenyl]-4-yl)-3-fluoro- |
Description | Synta66 is an inhibitor of store-operated calcium entry channel Orai, which forms the pore of the CRAC channel, and used for the research of neurological disease. |
---|---|
Related Catalog | |
Target |
Orai[1] |
In Vitro | Synta66 is an inhibitor of Orai, which forms the pore of the CRAC channel. Synta66 (10 μM) attenuates peak SOCE in Müller glia. Synta66 (10 μM) prevents orai channels mediating the residual SOC current in Trpc1−/− Müller cells[1]. Synta66 (10 μM) nearly completely blocks the Ca2+ entry signal evoked by CaCl2 addition, whereas it moderately reduces Ca2+ mobilization from stores with 10% to 30% in platelet. Synta66 (10 μM) suppresses human platelet activation in plasma and whole-blood thrombus formation. Synta66 (10 μM) also inhibits murine platelet responses and thrombus formation[2]. Synta66 (10 μM) inhibits LAD2 human mast cell line. Synta66 (10 μM) significantly inhibits FcεRI stimulated histamine and TNFα secretion, and has differential effects on FcεRI stimulated prostaglandin D2 and cytokine release in human lung mast cells (HLMCs)[3]. |
Cell Assay | Human Lung Mast Cell (HLMCs) are cultured in DMEM+Glutamax media containing 1% antibiotic-antimycotic solution, 1% non-essential amino acids, 10% fetal calf serum and supplemented with 100 ng/mL human stem cell factor, 50 ng/mL IL-6 and 10 ng/mL IL-10. For histamine assays mast cells are isolated from human lung tissue and used within 24 h[3]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 422.4±45.0 °C at 760 mmHg |
Molecular Formula | C20H17FN2O3 |
Molecular Weight | 352.359 |
Flash Point | 209.3±28.7 °C |
Exact Mass | 352.122314 |
LogP | 2.52 |
Vapour Pressure | 0.0±1.0 mmHg at 25°C |
Index of Refraction | 1.611 |
Storage condition | 2-8℃ |